BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

57.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗

January 11, 2023

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target ↗

January 11, 2023

Via Benzinga

6 Analysts Have This to Say About Biomarin Pharmaceutical ↗

January 11, 2023

Via Benzinga

2 Top Biotech Stocks Defying the Bear Market ↗

January 10, 2023

Some stocks are hitting new highs.

Via The Motley Fool

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 01, 2022

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

November 29, 2022

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

October 31, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday ↗

October 27, 2022

Investors were expecting better top-line numbers from the company's earnings report.

Via The Motley Fool

Expert Ratings for Biomarin Pharmaceutical ↗

October 13, 2022

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 01, 2022

Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate ↗

November 23, 2022

Via Benzinga

The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath ↗

November 23, 2022

And shares of its developer are on a warpath this week.

Via Investor's Business Daily

One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review ↗

October 13, 2022

Via Benzinga

BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company ↗

October 07, 2022

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

August 04, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today ↗

November 23, 2022

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...

Via Benzinga

$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying ↗

November 03, 2022

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

10 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 31, 2022

Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Mastercard To $428? Plus This Analyst Slashes PT On Intel ↗

October 31, 2022

Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...

Via Benzinga

Biomarin Pharmaceutical: Q3 Earnings Insights ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Recap: Biomarin Pharmaceutical Q3 Earnings ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial ↗

September 12, 2022

Via Benzinga

Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗

September 03, 2022

Neurocrine Biosciences leads five medical stocks showing resilience.

Via Investor's Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate ↗

August 24, 2022

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the...

Via Benzinga

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart ↗

August 09, 2022

If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.